Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 1 (2004), Issue 3 (October)

1. Follicle stimulating hormone-induced growth promotion and gene expression profiles on ovarian surface epithelial cells.
   Int J Cancer, 112(5): 803-14. [Abstract] [Full-text]
2. Significance of beta-catenin and pRB pathway components in malignant ovarian germ cell tumours: INK4A promoter CpG island methylation is associated with cell proliferation.
   J Pathol, 204(3): 268-76. [Abstract] [Full-text]
3. Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations.
   Eur J Hum Genet, 12(11): 899-906. [Abstract] [Full-text]
4. Full-thickness diaphragmatic resection with simple and secure closure to accomplish complete cytoreductive surgery for patients with ovarian cancer.
   Gynecol Oncol, 95(2): 384-7. [Abstract] [Full-text]
5. Factors associated with cytoreducibility among women with ovarian carcinoma.
   Gynecol Oncol, 95(2): 377-83. [Abstract] [Full-text]
6. Pretreatment serum hemoglobin level and a preliminary investigation of intratumoral microvessel density in advanced ovarian cancer.
   Gynecol Oncol, 95(2): 323-9. [Abstract] [Full-text]
7. Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8.
   Gynecol Oncol, 95(2): 314-22. [Abstract] [Full-text]
8. Placental leucine aminopeptidase (P-LAP) expression is associated with chemosensitivity in human endometrial carcinoma.
   Gynecol Oncol, 95(2): 307-13. [Abstract] [Full-text]
9. HMOCC-1, a human monoclonal antibody that inhibits adhesion of ovarian cancer cells to human mesothelial cells.
   Gynecol Oncol, 95(2): 290-8. [Abstract] [Full-text]
10. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer.
    Gynecol Oncol, 95(2): 273-80. [Abstract] [Full-text]
11. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
    Eur J Surg Oncol, 30(9): 976-81. [Abstract] [Full-text]
12. Synthesis, characterisation, activities, cell uptake and DNA binding of [[trans-PtCl(NH3)2] [mu-(H2N(CH2)6NH2)] [trans-PdCl(NH3)2](NO3)Cl.
    Eur J Med Chem, 39(11): 947-58. [Abstract] [Full-text]
13. Mutational spectrum of p53 mutations in primary breast and ovarian tumors.
    Crit Rev Oncol Hematol, 52(2): 103-16. [Abstract] [Full-text]
14. Biological evaluation of novel estrogen-platinum(II) hybrid molecules on uterine and ovarian cancers-molecular modeling studies.
    Bioorg Med Chem Lett, 14(23): 5919-24. [Abstract] [Full-text]
15. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling.
    J Biol Chem, 279(44): 45643-51. [Abstract] [Full-text]
16. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma.
    Apoptosis, 9(6): 797-805. [Abstract] [Full-text]
17. Dendritic cells fused with human cancer cells: morphology, antigen expression, and T cell stimulation.
    Clin Immunol, 113(3): 261-9. [Abstract] [Full-text]
18. Systematic review of adjuvant care for women with Stage I ovarian carcinoma.
    Cancer, 101(9): 1926-35. [Abstract] [Full-text]
19. Social support, anxiety and depression after chemotherapy for ovarian cancer: a prospective study.
    Br J Health Psychol, 9: 569-81. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.